Literature DB >> 23590802

Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade.

Gyan P Mishra1, Duc Nguyen, Adam W G Alani.   

Abstract

Angiogenesis is an essential process for disease progression in many solid tumors. There are several major cascade events in the angiogenic process that can be targeted to inhibit new blood vessel formation in the tumor tissue. The purpose of this work is to evaluate the inhibitory effect of paclitaxel (PTX) and rapamycin (RAP) as individual and in dual drug-loaded poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles on the angiogenic cascade processes of proliferation, migration, and tube formation. PEG-b-PLA PTX and/or RAP micelles were formed and characterized for size and drug loading. Sizes of individual and dual drug micelles were below 40 nm. PEG-b-PLA micelles significantly enhanced the aqueous solubility of PTX 1.80 mg/mL and RAP 1.60 mg/mL. The PTX-RAP dual drug PEG-b-PLA micelles were able to load PTX and RAP at 1.60 mg/mL for both drugs. Cell proliferation, apoptosis, tubule formation, and migration studies were performed in human umbilical vein endothelial cells (HUVEC). PTX and RAP in DMSO inhibited HUVEC proliferation with IC50 values of 0.82 ± 0.02 and 13 829 ± 681 nM, respectively, while the combination of both drugs in DMSO produced synergistic inhibition. PTX and RAP individual micelles had IC50 values of 6.3 ± 1.1 and 14 051 ± 821 nM, respectively. PTX and dual drug micelles had a synergistic inhibition effect on HUVEC proliferation through the induction of apoptosis via caspase 3/7 activity. In vitro tube formation assay demonstrated significant inhibition of tube formation upon treatment with dual drug micelles as compared to individual PTX or RAP micelles. Migration studies in HUVEC have shown that individual PTX micelles inhibited cell migration at 1 nM, while RAP micelles did not show any inhibitory effect on cell migration. Interestingly, the presence of RAP in the dual drug micelles was able to initiate the inhibition of the migration of HUVEC at 0.1 nM concentration of PTX. These results indicate that PTX-RAP dual drug micelles have antiangiogenic effects in vitro mediated through three major events in the angiogenic process and have strong potential for further development as antiangiogenic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590802     DOI: 10.1021/mp400122m

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

Review 1.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

2.  Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells†Electronic supplementary information (ESI) available: Chemicals and reagents, detailed experimental procedures for materials synthesis, characterization, cellular evaluations and supporting figures and tables. See DOI: 10.1039/c4tb01633eClick here for additional data file.

Authors:  Wei Tian; Jieying Liu; Yuan Guo; Yuanyuan Shen; Dejian Zhou; Shengrong Guo
Journal:  J Mater Chem B       Date:  2015-01-27       Impact factor: 6.331

3.  Polymeric Micelles as Carriers for Nerve-Highlighting Fluorescent Probe Delivery.

Authors:  Kayla M Hackman; Bhuvana Shyam Doddapaneni; Connor W Barth; Igor H Wierzbicki; Adam W G Alani; Summer L Gibbs
Journal:  Mol Pharm       Date:  2015-11-12       Impact factor: 4.939

4.  Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules.

Authors:  E Villar-Alvarez; A Cambón; A Pardo; L Arellano; A V Marcos; B Pelaz; P Del Pino; A Bouzas Mosquera; V X Mosquera; A Almodlej; G Prieto; S Barbosa; P Taboada
Journal:  J Nanobiotechnology       Date:  2019-10-15       Impact factor: 10.435

5.  Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer.

Authors:  Dong Mei; Binlong Chen; Bing He; Haibin Liu; Zhiqiang Lin; Jialiang Lin; Xiaoyan Zhang; Ning Sun; Libo Zhao; Xiaoling Wang; Qiang Zhang
Journal:  Acta Pharm Sin B       Date:  2019-04-05       Impact factor: 11.413

6.  Disruption of microtubule function in cultured human cells by a cytotoxic ruthenium(ii) polypyridyl complex.

Authors:  Nagham Alatrash; Faiza H Issa; Nada S Bawazir; Savannah J West; Kathleen E Van Manen-Brush; Charles P Shelor; Adam S Dayoub; Kenneth A Myers; Christopher Janetopoulos; Edwin A Lewis; Frederick M MacDonnell
Journal:  Chem Sci       Date:  2019-11-18       Impact factor: 9.825

7.  A targeted combinatorial therapy for Ewing's sarcoma.

Authors:  Fahad Y Sabei; Olena Taratula; Hassan A Albarqi; Adel M Al-Fatease; Abraham S Moses; Ananiya A Demessie; Youngrong Park; Walter K Vogel; Ellie Esfandiari Nazzaro; Monika A Davare; Adam Alani; Mark Leid; Oleh Taratula
Journal:  Nanomedicine       Date:  2021-07-23       Impact factor: 6.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.